ArticleFrontiers in medicine2025
Global, regional, and national epidemiology of thyroid cancer in middle-aged and elderly adults from 1990 to 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer (TC) has shown dynamic changes in its global burden over the past decades. This study aimed to evaluate trends in incidence, mortality, and disability-adjusted life years (DALYs) of TC among middle-aged and elderly adults across 204 countries and territories from 1990 to 2021. Methods: Data were extracted from the Global Burden of Disease Study 2021. Age-standardized rates (ASRs) of incidence, death, and DALYs, estimated annual percentage change (EAPC), and the sociodemographic index (SDI) were used to quantify trends. A Bayesian age-period-cohort (BAPC) model was employed to predict future burden through 2035, and global risk-attributable factors were assessed. Results: Globally, TC incidence cases among adults aged 55 and older increased by 185% from 1990 to 2021, with deaths and DALYs rising by 116 and 108%, respectively. The age-standardized incidence rate rose significantly (EAPC = 0.95), while mortality and DALY rates slightly declined. Most regions showed rising incidence, with the exception of Central Europe. Females consistently exhibited higher TC burden, but the gender gap is gradually narrowing. Peak incidence occurred at ages 70-74 for females and 85-89 for males in 2021. High body mass index (BMI) emerged as the leading modifiable risk factor. Conclusion: The rising burden of thyroid cancer in aging populations calls for integrated health policies emphasizing prevention, early detection, and public education. Efforts should focus on reducing modifiable risks, particularly high BMI, and developing age- and sex-specific interventions. Addressing gender disparities and regional inequalities should also be central to global and national cancer control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.